Evidence map›Paper›PMID 34922619›Full record

ArticleClinical epigenetics2021

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer.

Braydon Meyer, Samuel Clifton, Warwick Locke, Phuc-Loi Luu, Qian Du, Dilys Lam, Nicola J Armstrong, Beena Kumar, Niantao Deng, Kate Harvey and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epigenetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Braydon MeyerEpigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia.
Samuel CliftonEpigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia.
Warwick LockeMolecular Diagnostics Solutions, CSIRO Health and Biosecurity, New South Wales, North Ryde, 2113, Australia.
Phuc-Loi LuuEpigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia.
Qian DuEpigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia.
Dilys LamEpigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia.
Nicola J ArmstrongDepartment of Mathematics and Statistics, Curtin University, Perth, WA, 6103, Australia.
Beena KumarHudson Institute of Medical Research, Clayton, VIC, 3168, Australia.
Niantao DengSt. Vincent's Clinical School, UNSW Australia, Sydney, NSW, 2010, Australia.
Kate HarveyCancer Research Theme, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia.
Alex SwarbrickSt. Vincent's Clinical School, UNSW Australia, Sydney, NSW, 2010, Australia.
Vinod Ganju *Hudson Institute of Medical Research, Clayton, VIC, 3168, Australia.
Susan J Clark *Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia. s.clark@garvan.org.au.
Ruth Pidsley *Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia. r.pidsley@garvan.org.au.
Clare Stirzaker *Epigenetics Research Laboratory, Genomics and Epigenetics Theme, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW, 2010, Australia. c.stirzaker@garvan.org.au.ORCID 0000-0001-5601-3140
Garvan Institute of Medical Research · AUHudson Institute of Medical Research · AUCSIRO Health and Biosecurity · AUCurtin University · AU

Funding

Cancer Council NSW RG-18-09National Breast Cancer Foundation IIRS-18-137National Health and Medical Research Council 1063559National Health and Medical Research Council 1106870National Health and Medical Research Council 1156408
6 · The paper itself

Abstract

Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient's response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative (SETUP) NAC study. We found 9 significantly differentially methylated regions (DMRs) at diagnosis which were associated with response to NAC. We show that 4 of these DMRs are associated with TNBC overall survival (P < 0.05). Our results highlight the potential of DNA methylation biomarkers for predicting NAC response in TNBC.

Indexed as

AdultBiomarkers, PharmacologicalBiomarkers, TumorDNA MethylationFemaleHumansMiddle AgedNeoadjuvant TherapyPrognosisProportional Hazards ModelsTriple Negative Breast NeoplasmsBiomarkers, PharmacologicalBiomarkers, TumorDNA methylationEpigeneticsMethylomeNeoadjuvant chemotherapyTriple-negative breast cancer

Identifiers

PMID34922619
PMCPMC8684655
OpenAlexW4200548140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.